NASDAQ:ASND - Ascendis Pharma A/S Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $191.88
  • Forecasted Upside: 14.01 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$168.30
▲ +10.58 (6.71%)

This chart shows the closing price for ASND by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ascendis Pharma A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ASND and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ASND

Analyst Price Target is $191.88
▲ +14.01% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Ascendis Pharma A/S in the last 3 months. The average price target is $191.88, with a high forecast of $216.00 and a low forecast of $175.00. The average price target represents a 14.01% upside from the last price of $168.30.

This chart shows the closing price for ASND for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Ascendis Pharma A/S. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/1/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/30/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/28/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/27/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/27/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/26/2021WedbushReiterated RatingBuy$187.00High
8/26/2021Morgan StanleyBoost Price TargetOverweight$197.00 ➝ $204.00High
8/26/2021JPMorgan Chase & Co.Boost Price TargetOverweight$172.00 ➝ $175.00High
8/26/2021Credit Suisse GroupBoost Price TargetOutperform$178.00 ➝ $185.00High
8/26/2021SVB LeerinkBoost Price TargetOutperform$178.00 ➝ $182.00High
7/21/2021SVB LeerinkLower Price TargetOutperform$181.00 ➝ $178.00Low
7/8/2021OppenheimerReiterated RatingHoldMedium
6/14/2021SVB LeerinkLower Price TargetPositive ➝ Outperform$191.00 ➝ $181.00High
6/14/2021WedbushLower Price TargetOutperform$219.00 ➝ $189.00High
6/14/2021Morgan StanleyLower Price TargetOverweight$201.00 ➝ $197.00High
6/1/2021Canaccord GenuityBoost Price TargetBuy$190.00 ➝ $196.00Low
5/28/2021Credit Suisse GroupBoost Price TargetOutperform$176.00 ➝ $178.00High
5/28/2021Morgan StanleyBoost Price TargetOverweight$199.00 ➝ $201.00Medium
3/30/2021OppenheimerDowngradeOutperform ➝ Market PerformLow
3/12/2021Canaccord GenuityBoost Price TargetBuy$172.00 ➝ $190.00Low
3/11/2021Credit Suisse GroupLower Price TargetOutperform$178.00 ➝ $176.00Low
3/11/2021Stifel NicolausInitiated CoverageBuyHigh
12/17/2020Berenberg BankInitiated CoverageBuy$216.00Low
11/13/2020Morgan StanleyBoost Price TargetOverweight$194.00 ➝ $199.00Low
11/12/2020Wells Fargo & CompanyBoost Price TargetOverweight$176.00 ➝ $190.00High
11/12/2020Credit Suisse GroupBoost Price TargetOutperform$158.00 ➝ $178.00High
11/12/2020SVB LeerinkBoost Price TargetOutperform$173.00 ➝ $191.00High
10/13/2020Morgan StanleyBoost Price TargetOverweight$179.00 ➝ $194.00Low
9/30/2020WedbushBoost Price TargetOutperform$187.00 ➝ $206.00Medium
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweightMedium
8/31/2020Morgan StanleyBoost Price TargetOverweight$177.00 ➝ $179.00High
8/28/2020Credit Suisse GroupBoost Price TargetOutperform$154.00 ➝ $158.00Medium
7/15/2020Morgan StanleyLower Price TargetOverweight$181.00 ➝ $177.00Low
6/26/2020WedbushInitiated CoverageBuy$188.00Low
5/21/2020Morgan StanleyBoost Price TargetOverweight$180.00 ➝ $181.00Low
5/20/2020CSFBBoost Price TargetOutperform$149.00 ➝ $154.00Medium
5/20/2020SVB LeerinkBoost Price TargetOutperform$170.00 ➝ $173.00Low
5/20/2020Credit Suisse GroupBoost Price TargetOutperform$149.00 ➝ $154.00High
5/20/2020OppenheimerLower Price TargetOutperform$219.00 ➝ $208.00High
4/20/2020SVB LeerinkBoost Price TargetPositive ➝ Outperform$152.00 ➝ $170.00High
4/20/2020JPMorgan Chase & Co.Boost Price TargetOverweight$145.00 ➝ $150.00High
4/20/2020OppenheimerBoost Price TargetOutperform$199.00 ➝ $219.00High
4/20/2020Canaccord GenuityBoost Price TargetBuy$166.00 ➝ $170.00High
4/20/2020Credit Suisse GroupBoost Price TargetIn-Line ➝ Outperform$139.00 ➝ $149.00High
4/20/2020Cantor FitzgeraldBoost Price TargetOverweight$185.00 ➝ $201.00High
4/20/2020Stifel NicolausBoost Price TargetBuy$146.00 ➝ $171.00High
4/2/2020Morgan StanleyLower Price TargetOverweight$181.00 ➝ $180.00Medium
3/31/2020Canaccord GenuityBoost Price TargetBuy$144.00 ➝ $166.00High
3/27/2020Bank of AmericaReiterated RatingBuy$145.00Medium
3/19/2020OppenheimerInitiated CoverageOutperform$199.00Low
2/26/2020Morgan StanleyBoost Price TargetOverweight$148.00 ➝ $181.00Low
1/17/2020Morgan StanleyBoost Price TargetOverweight$140.00 ➝ $148.00Medium
12/17/2019Morgan StanleyBoost Price TargetOverweight$134.00 ➝ $140.00High
12/3/2019SVB LeerinkReiterated RatingPositive ➝ Outperform$140.00 ➝ $152.00Medium
11/19/2019WedbushReiterated RatingBuy$186.00High
10/22/2019WedbushLower Price TargetPositive ➝ Outperform$191.00 ➝ $186.00High
10/11/2019Morgan StanleyInitiated CoverageOverweight$128.00High
9/24/2019WedbushSet Price TargetBuy$191.00Low
8/29/2019JPMorgan Chase & Co.Boost Price TargetOverweight$143.00 ➝ $152.00High
6/28/2019WedbushReiterated RatingBuy$223.00Low
6/10/2019WedbushSet Price TargetBuy$223.00Low
6/3/2019WedbushBoost Price TargetOutperform$219.00 ➝ $223.00High
5/31/2019Canaccord GenuityBoost Price TargetBuy$133.00 ➝ $144.00High
5/20/2019WedbushSet Price TargetBuy$219.00Medium
4/8/2019WedbushReiterated RatingBuy$219.00High
4/5/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$132.00 ➝ $133.00Low
3/29/2019Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$151.00 ➝ $139.00Low
3/26/2019WedbushReiterated RatingBuy$217.00Medium
3/25/2019Evercore ISIInitiated CoverageOutperform ➝ OutperformHigh
3/18/2019Cantor FitzgeraldReiterated RatingBuy$185.00Low
3/7/2019WedbushSet Price TargetOutperform$81.00 ➝ $217.00Medium
3/7/2019JPMorgan Chase & Co.Boost Price TargetOverweight$85.00 ➝ $145.00Medium
3/4/2019Cantor FitzgeraldReiterated RatingOverweight$102.00 ➝ $185.00High
1/25/2019WedbushSet Price TargetBuy$81.00High
1/24/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$73.00 ➝ $90.00Low
1/23/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$102.00Low
11/29/2018Credit Suisse GroupBoost Price TargetOutperform$80.00 ➝ $86.00High
11/9/2018Credit Suisse GroupInitiated CoverageOutperform$80.00Low
8/30/2018WedbushSet Price TargetBuy$79.00Low
8/30/2018JPMorgan Chase & Co.Boost Price TargetOverweight$79.00 ➝ $81.00Low
8/30/2018Wells Fargo & CompanyBoost Price TargetOutperform$83.00 ➝ $88.00High
8/30/2018Stifel NicolausLower Price TargetBuy ➝ Buy$85.00 ➝ $81.00High
8/7/2018Canaccord GenuityInitiated CoverageBuy$81.00Low
6/26/2018Stifel NicolausInitiated CoverageBuy$85.00Medium
5/31/2018SVB LeerinkReiterated RatingMarket Perform$64.00 ➝ $70.00Medium
5/15/2018WedbushReiterated RatingOutperform$76.00Low
4/20/2018WedbushReiterated RatingTop Pick$76.00High
4/4/2018WedbushLower Price TargetOutperform$76.00 ➝ $67.00Low
4/2/2018SVB LeerinkReiterated RatingMkt Perform ➝ Market Perform$37.00 ➝ $64.00High
3/21/2018JPMorgan Chase & Co.Boost Price TargetOverweight$75.00High
3/20/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$50.00 ➝ $78.00High
2/26/2018WedbushReiterated RatingOutperform$67.00Low
2/25/2018Credit Suisse GroupReiterated RatingBuy$50.00Low
2/6/2018WedbushReiterated RatingOutperform$62.00Low
1/25/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$45.00 ➝ $60.00High
1/19/2018HC WainwrightReiterated RatingBuyMedium
1/17/2018JPMorgan Chase & Co.Reiterated RatingBuy$60.00Medium
1/3/2018JPMorgan Chase & Co.Set Price TargetBuy$50.00Low
12/13/2017HC WainwrightReiterated RatingBuyLow
11/17/2017Bank of AmericaLower Price TargetBuy$46.00 ➝ $43.00N/A
9/28/2017Bank of AmericaBoost Price Target$36.00 ➝ $46.00Low
9/25/2017Bank of AmericaReiterated RatingBuy$34.00 ➝ $36.00High
9/22/2017Wells Fargo & CompanyReiterated RatingBuy$51.00High
9/22/2017Credit Suisse GroupReiterated RatingOutperform$30.00 ➝ $50.00High
9/22/2017WedbushReiterated RatingOutperform$65.00 ➝ $10.71High
9/1/2017SVB LeerinkReiterated RatingHold$28.00High
7/18/2017Credit Suisse GroupSet Price TargetBuy$28.00High
5/25/2017SVB LeerinkLower Price TargetMarket Perform$30.00 ➝ $26.00Low
5/24/2017WedbushReiterated RatingOutperform$36.00 ➝ $34.00Low
5/11/2017JPMorgan Chase & Co.Initiated CoverageOverweight$36.00Low
4/3/2017WedbushReiterated RatingOutperform$34.00Low
3/24/2017WedbushBoost Price TargetOutperform$31.00 ➝ $34.00High
3/9/2017SVB LeerinkDowngradeOutperform ➝ Market Perform$24.00 ➝ $30.00Low
2/23/2017WedbushReiterated RatingOutperform$31.00N/A
2/9/2017Credit Suisse GroupInitiated CoverageOutperform$28.00N/A
2/8/2017WedbushReiterated RatingOutperform$31.00N/A
12/16/2016WedbushReiterated RatingOutperform$31.00N/A
12/1/2016SVB LeerinkReiterated RatingBuy$24.00N/A
12/1/2016WedbushReiterated RatingOutperform$31.00N/A
10/20/2016WedbushReiterated RatingOutperform$31.00N/A
9/26/2016WedbushInitiated CoverageOutperform$34.00N/A
(Data available from 9/24/2016 forward)

News Sentiment Rating

0.69 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/26/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2021
  • 9 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/24/2021

Current Sentiment

  • 9 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Ascendis Pharma A/S logo
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
Read More

Today's Range

Now: $168.30
Low: $156.98
High: $169.84

50 Day Range

MA: $137.01
Low: $112.67
High: $176.92

52 Week Range

Now: $168.30
Low: $109.36
High: $183.98

Volume

256,607 shs

Average Volume

219,908 shs

Market Capitalization

$9.49 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Ascendis Pharma A/S?

The following Wall Street sell-side analysts have issued stock ratings on Ascendis Pharma A/S in the last year: Berenberg Bank, Canaccord Genuity, Credit Suisse Group AG, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Stifel Nicolaus, SVB Leerink LLC, Wedbush, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for ASND.

What is the current price target for Ascendis Pharma A/S?

8 Wall Street analysts have set twelve-month price targets for Ascendis Pharma A/S in the last year. Their average twelve-month price target is $191.88, suggesting a possible upside of 14.0%. Berenberg Bank has the highest price target set, predicting ASND will reach $216.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $175.00 for Ascendis Pharma A/S in the next year.
View the latest price targets for ASND.

What is the current consensus analyst rating for Ascendis Pharma A/S?

Ascendis Pharma A/S currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ASND will outperform the market and that investors should add to their positions of Ascendis Pharma A/S.
View the latest ratings for ASND.

How do I contact Ascendis Pharma A/S's investor relations team?

Ascendis Pharma A/S's physical mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company's listed phone number is (457) 022-2244 and its investor relations email address is [email protected] The official website for Ascendis Pharma A/S is www.ascendispharma.com.